Therapeutic | Glembatumumab |
Target | GPNMB |
Heavy Chain | QVQLQESGPGLVKPSQTLSLTCTVSGGSISSFNYYWSWIRHHPGKGLEWIGYIYYSGSTYSNPSLKSRVTISVDTSKNQFSLTLSSVTAADTAVYYCARGYNWNYFDYWGQGTLVTVSS |
Light Chain | EIVMTQSPATLSVSPGERATLSCRASQSVDNNLVWYQQKPGQAPRLLIYGASTRATGIPARFSGSGSGTEFTLTISSLQSEDFAVYYCQQYNNWPPWTFGQGTKVEIK |
100% seqID Fv Structure | None |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
Follow these links to our prediction tools:
Format | Whole mAb ADC |
Isotype | G2 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Discontinued |
Recorded Developmental Technology | na |
INN Year Proposed | 2015 |
INN Year Recommended | 2016 |
Companies Involved | CuraGen Corporation, Celldex Therapeutics Inc, National Cancer Institute (USA) |
Conditions Approved | na |
Conditions Active | na |
Conditions Discontinued | Brain cancer, Breast cancer, Malignant melanoma, Osteosarcoma, Squamous cell cancer, Uveal melanoma |
Notes |